Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Active, not recruiting · Phase 1, Phase 2 · NCT04557956
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 16
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Biopsy Procedure (procedure), Computed Tomography (procedure), Dabrafenib Mesylate (drug), Echocardiography Test (procedure), Magnetic Resonance Imaging (procedure), Multigated Acquisition Scan (procedure), Tazemetostat Hydrobromide (drug), Trametinib Dimethyl Sulfoxide (drug)
- Dates
- Started 2021-08-19; completion 2027-03-11
- Results posted
- Yes
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma.
From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $1.1M in research payments for this study in 2025 (2 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Cancer Institute Frederick Campus $1.0M
- Nci Cancer Therapy Evaluation Program $35,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.